RNS Number : 3879F

Tiziana Life Sciences PLC

26 October 2018

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR
THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

Tiziana Life Sciences plc

("Tiziana" or the "Company")

Equity Placing to raise US$1,500,000

London, October 26, 2018 - Tiziana Life Sciences plc (AIM: TILS), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it has raised US$1,500,000 by the issue of 1,515,150 new ordinary shares ("Placing Shares") at a price of US$0.99 (75p) per share at a fixed exchange rate of GBP 1 : US$ 1.32 (the "Placing").

Application will be made to London Stock Exchange plc to admit the Placing Shares to trading on AIM ("Admission") with Admission expected to occur on or around 19 November 2018.  The Placing Shares will rank pari passu with the existing ordinary shares of nominal value 3 pence each in the capital of the Company (the "Ordinary Shares").

Following Admission, the fully diluted issued share capital of the Company will consist of 151,790,735 Ordinary Shares (assuming all options and warrants, vested and unvested, exercised and exercisable, were converted).

Total Voting Rights

In conformity with DTR 5.6.1, the Company notifies that as at the date of this announcement, it has a single class of shares in issue being Ordinary Shares and that following the issue of the Placing Shares, the total number of Ordinary Shares in issue will be 128,442,449.  There are no Ordinary Shares held in treasury.  Each Ordinary Share entitles the holder to a single vote at general meetings of the Company. 

The figure of 128,442,449 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The person who arranged for release of this announcement on behalf of the Company was Tiziano Lazzaretti, Chief Financial Officer of Tiziana.

 

For further enquiries:

Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder

+44 (0)20 7493 2853

 

Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner	+44 (0)20 7213 0883
Stockdale Securities Limited (Broker) Andy Crossley / Antonio Bossi / David Coaten	+44 (0)20 7601 6100

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

 

END

 

 

IOEQQLFLVBFLFBK